LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

Начало・Списък с акции・Anavex Life Sciences Corp

Anavex Life Sciences Corp

Затворен

СекторЗдравеопазване

2.63 -5.4

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

2.6

Максимум

2.77

Ключови измерители
By Trading Economics
Приходи	4.1M -5.7M
Служители	34
EBITDA	3.1M -6.8M

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+619.42% upside

Дивиденти
By Dow Jones
Следващи печалби	9.06.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-113M 276M
Предишно отваряне	8.03
Предишно затваряне	2.63

Настроения в новините

By Acuity

50%

147 / 344 Класиране в Healthcare

Anavex Life Sciences Corp Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

2.06.2026 г., 20:30 ч. UTC

Печалби

Palo Alto Networks 3Q Revenue Rises as Customers Beef Up Cyber Defenses

2.06.2026 г., 23:58 ч. UTC

Пазарно говорене

Australia's Consumer Sector Expected to Be Stung by Housing Downturn -- Market Talk

2.06.2026 г., 23:46 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

2.06.2026 г., 23:46 ч. UTC

Пазарно говорене

Nikkei May Rise as AI Demand Hopes Continue -- Market Talk

2.06.2026 г., 23:41 ч. UTC

Пазарно говорене

Oil Rises Amid Signs of U.S.-Iran Peace Talks Stalling -- Market Talk

2.06.2026 г., 23:01 ч. UTC

Придобивния, сливания и поглъщания

ACCC Says Owner of Metro Petroleum Brand to Buy the 41 Sites

2.06.2026 г., 23:01 ч. UTC

Придобивния, сливания и поглъщания

ACCC Says Ampol Must Sell 41 Retail Fuel Sites to an Approved Purchaser

2.06.2026 г., 23:00 ч. UTC

Придобивния, сливания и поглъщания

Australia's Competition Regulator Approves Ampol's Purchase of EG Australia With Conditions

2.06.2026 г., 22:57 ч. UTC

Пазарно говорене

Australian Dollar Could Fall Following 1Q GDP Data -- Market Talk

2.06.2026 г., 22:50 ч. UTC

Пазарно говорене

Ulta Beauty Says TikTok Shop Will Provide 'Halo' Effect -- Market Talk

2.06.2026 г., 21:07 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

2.06.2026 г., 21:07 ч. UTC

Пазарно говорене

Tokenized Assets Need Access to Digital-Finance Plumbing -- Market Talk

2.06.2026 г., 21:00 ч. UTC

Печалби

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2.06.2026 г., 20:50 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

2.06.2026 г., 20:46 ч. UTC

Печалби

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2.06.2026 г., 20:38 ч. UTC

Печалби

GitLab Stock Rises as the Software Company Raises Guidance on AI Business Momentum -- Barrons.com

2.06.2026 г., 20:21 ч. UTC

Печалби

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2.06.2026 г., 20:12 ч. UTC

Печалби

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2.06.2026 г., 20:05 ч. UTC

Печалби

Palo Alto Networks 3Q Product Rev $594M

2.06.2026 г., 20:05 ч. UTC

Печалби

Palo Alto Networks Sees FY26 Next-Generation Security ARR $8.9B-$8.95B

2.06.2026 г., 20:05 ч. UTC

Печалби

Palo Alto Networks Raises FY26 View To Adj EPS $3.77-Adj EPS $3.79 >PANW

2.06.2026 г., 20:05 ч. UTC

Печалби

Palo Alto Networks 3Q Subscription and Support Rev $2.41B

2.06.2026 г., 20:05 ч. UTC

Печалби

Palo Alto Networks Sees FY26 Remaining Performance Obligation $20.9B-$21B

2.06.2026 г., 20:05 ч. UTC

Печалби

Palo Alto Networks Sees 4Q Rev $3.345B-$3.355B >PANW

2.06.2026 г., 20:05 ч. UTC

Печалби

Palo Alto Networks Sees 4Q Adj EPS 96c-Adj EPS 98c >PANW

2.06.2026 г., 20:05 ч. UTC

Печалби

Palo Alto Networks on Track to Achieve 40% Adj Free Cash Flow Margin in FY28

2.06.2026 г., 20:05 ч. UTC

Печалби

Palo Alto Networks Raises FY26 View To Rev $11.415B-$11.425B >PANW

2.06.2026 г., 20:05 ч. UTC

Печалби

Palo Alto Networks 3Q Remaining Performance Obligation $18.4B

2.06.2026 г., 20:05 ч. UTC

Печалби

Palo Alto Networks 3Q Adj EPS 85c >PANW

2.06.2026 г., 20:05 ч. UTC

Печалби

Palo Alto Networks 3Q Loss $177M >PANW

Сравнение с други в отрасъла

Ценова промяна

Anavex Life Sciences Corp Прогноза

Ценова цел

By TipRanks

619.42% нагоре

12-месечна прогноза

Среден 20 USD 619.42%

Висок 20 USD

Нисък 20 USD

Според 2 анализатори от Wall Street, предложили 12-месечна ценова цел за Anavex Life Sciences Corp през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

2 ratings

Купи

Задържане

Продай

Според 2 анализатори, дали борсови рейтинги на Anavex Life Sciences Corp през последните 3 месеца.

Настроение

By Acuity

147 / 344 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Anavex Life Sciences Corp

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.